Executive Summary
Chr. Hansen Holding A/S, a bioscience company, develops and sells natural ingredient solutions for food, nutritional, pharmaceutical, and agricultural industries in Europe, the Middle East, Africa, North America, Latin America, and the Asia-Pacific.
Rewards
Risk Analysis
Snowflake Analysis
Solid track record with mediocre balance sheet.
Similar Companies
Share Price & News
How has Chr. Hansen Holding's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CHR has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
2.5%
CHR
1.7%
DK Chemicals
1.8%
DK Market
1 Year Return
-12.1%
CHR
15.7%
DK Chemicals
23.0%
DK Market
Return vs Industry: CHR underperformed the Danish Chemicals industry which returned 15.7% over the past year.
Return vs Market: CHR underperformed the Danish Market which returned 23% over the past year.
Shareholder returns
| CHR | Industry | Market | |
|---|---|---|---|
| 7 Day | 2.5% | 1.7% | 1.8% |
| 30 Day | -0.4% | -1.0% | 2.9% |
| 90 Day | -10.0% | 3.8% | 9.2% |
| 1 Year | -10.1%-12.1% | 20.2%15.7% | 26.8%23.0% |
| 3 Year | 46.7%37.1% | 20.9%9.9% | 57.4%44.0% |
| 5 Year | 125.4%101.9% | 52.3%29.7% | 89.3%63.2% |
Price Volatility Vs. Market
How volatile is Chr. Hansen Holding's share price compared to the market and industry in the last 5 years?
Simply Wall St News
5 days ago | Simply Wall St
Is Chr. Hansen Holding A/S's (CPH:CHR) 31% ROE Better Than Average?2 weeks ago | Simply Wall St
Chr. Hansen Holding A/S (CPH:CHR) Is About To Go Ex-Dividend, And It Pays A 1.4% Yield1 month ago | Simply Wall St
Chr. Hansen Holding A/S (CPH:CHR)'s Earnings Grew 9.6%, Is It Enough?Valuation
Is Chr. Hansen Holding undervalued compared to its fair value and its price relative to the market?
37.13x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: CHR (DKK527) is trading above our estimate of fair value (DKK291.63)
Significantly Below Fair Value: CHR is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: CHR is poor value based on its PE Ratio (37.1x) compared to the Chemicals industry average (17.7x).
PE vs Market: CHR is poor value based on its PE Ratio (37.1x) compared to the Danish market (15.4x).
Price to Earnings Growth Ratio
PEG Ratio: CHR is poor value based on its PEG Ratio (4.9x)
Price to Book Ratio
PB vs Industry: CHR is overvalued based on its PB Ratio (11.6x) compared to the XE Chemicals industry average (1.6x).
Next Steps
Future Growth
How is Chr. Hansen Holding forecast to perform in the next 1 to 3 years based on estimates from 11 analysts?
7.5%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CHR's forecast earnings growth (7.5% per year) is above the savings rate (-0.3%).
Earnings vs Market: CHR's earnings (7.5% per year) are forecast to grow slower than the Danish market (12.1% per year).
High Growth Earnings: CHR's earnings are forecast to grow, but not significantly.
Revenue vs Market: CHR's revenue (6.3% per year) is forecast to grow slower than the Danish market (6.7% per year).
High Growth Revenue: CHR's revenue (6.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CHR's Return on Equity is forecast to be high in 3 years time (31.3%)
Next Steps
Past Performance
How has Chr. Hansen Holding performed over the past 5 years?
12.3%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CHR has high quality earnings.
Growing Profit Margin: CHR's current net profit margins (21.5%) are higher than last year (20.8%).
Past Earnings Growth Analysis
Earnings Trend: CHR's earnings have grown by 12.3% per year over the past 5 years.
Accelerating Growth: CHR's earnings growth over the past year (9.6%) is below its 5-year average (12.3% per year).
Earnings vs Industry: CHR earnings growth over the past year (9.6%) exceeded the Chemicals industry 1.8%.
Return on Equity
High ROE: CHR's Return on Equity (31.4%) is considered high.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is Chr. Hansen Holding's financial position?
Financial Position Analysis
Short Term Liabilities: CHR's short term assets (€474.0M) exceed its short term liabilities (€360.9M).
Long Term Liabilities: CHR's short term assets (€474.0M) do not cover its long term liabilities (€899.7M).
Debt to Equity History and Analysis
Debt Level: CHR's debt to equity ratio (96%) is considered high.
Reducing Debt: CHR's debt to equity ratio has increased from 70.3% to 96% over the past 5 years.
Debt Coverage: CHR's debt is well covered by operating cash flow (39%).
Interest Coverage: CHR's interest payments on its debt are well covered by EBIT (30.9x coverage).
Balance Sheet
Inventory Level: CHR has a high level of physical assets or inventory.
Debt Coverage by Assets: CHR's debt is not covered by short term assets (assets are 0.6x debt).
Next Steps
Dividend
What is Chr. Hansen Holding's current dividend yield, its reliability and sustainability?
2.53%
Current Dividend Yield
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: CHR's dividend (2.53%) is higher than the bottom 25% of dividend payers in the Danish market (1.52%).
High Dividend: CHR's dividend (2.53%) is low compared to the top 25% of dividend payers in the Danish market (5.02%).
Stability and Growth of Payments
Stable Dividend: CHR has been paying a dividend for less than 10 years and during this time payments have been volatile.
Growing Dividend: CHR's dividend payments have increased, but the company has only paid a dividend for 9 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonable payout ratio (50%), CHR's dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: CHR's dividends in 3 years are forecast to be covered by earnings (64.3% payout ratio).
Next Steps
Management
What is the CEO of Chr. Hansen Holding's salary, the management and board of directors tenure and is there insider trading?
3.3yrs
Average management tenure
CEO
Mauricio Graber (56yo)
1.5yrs
Tenure
€3,101,000
Compensation
Mr. Mauricio Graber has been Chief Executive Officer, President and Member of Executive Board of Chr. Hansen Holding A/S since joining it on June 1, 2018. Mr. Graber served as the President of Flavour Divi ...
CEO Compensation Analysis
Compensation vs Market: Mauricio's total compensation ($USD3.44M) is about average for companies of similar size in the Danish market ($USD2.82M).
Compensation vs Earnings: Mauricio's compensation has been consistent with company performance over the past year.
Management Age and Tenure
3.3yrs
Average Tenure
50.5yo
Average Age
Experienced Management: CHR's management team is considered experienced (3.3 years average tenure).
Board Age and Tenure
2.1yrs
Average Tenure
59yo
Average Age
Experienced Board: CHR's board of directors are not considered experienced ( 2.1 years average tenure), which suggests a new board.
Insider Trading
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Management Team
Alice Larsen (51yo)
Corporate Vice President of Global Human Resources
- Tenure: 3.4yrs
Søren Lonning (42yo)
CFO, Executive VP & Member of Executive Board
- Tenure: 4.3yrs
- Compensation: €966.00k
Mauricio Graber (56yo)
CEO, President & Member of Executive Board
- Tenure: 1.5yrs
- Compensation: €3.10m
Winnie Bügel (54yo)
Corporate Vice President of Compliance
- Tenure: 3.5yrs
Jacob Paulsen (43yo)
Executive Vice President of Food Cultures & Enzymes
- Tenure: 3.3yrs
Thomas Schäfer (56yo)
Executive VP
- Tenure: 2.1yrs
- Compensation: €636.00k
Christian Barker (49yo)
Executive Vice President of Health & Nutrition
- Tenure: 0yrs
Camilla Lercke
Head of Media Relations
- Tenure: 0yrs
Torsten Steenholt (50yo)
Executive Vice President of Global Operations
- Tenure: 2.9yrs
Martin Riise
Head of Investor Relations
- Tenure: 0yrs
Board Members
Jesper Brandgaard (56yo)
Independent Vice Chairman
- Tenure: 0yrs
- Compensation: €127.00k
Dominique J. Reiniche (64yo)
Independent Chairman of the Board
- Tenure: 1.1yrs
- Compensation: €217.00k
Luis Cantarell Rocamora (67yo)
Independent Director
- Tenure: 3.1yrs
- Compensation: €88.00k
Mark Wilson (67yo)
Independent Director
- Tenure: 9.2yrs
- Compensation: €129.00k
Heidi Kleinbach-Sauter (62yo)
Director
- Tenure: 2.1yrs
- Compensation: €87.00k
Kristian Villumsen (49yo)
Independent Director
- Tenure: 5.1yrs
- Compensation: €91.00k
Per Poulsen (53yo)
Employee Representative Director
- Tenure: 6.1yrs
- Compensation: €54.00k
Lisbeth Grubov (64yo)
Employee Representative Director
- Tenure: 2.1yrs
- Compensation: €57.00k
Charlotte Hemmingsen (55yo)
Employee Representative Director
- Tenure: 2.1yrs
- Compensation: €54.00k
Kim Soerensen (56yo)
Employee Representative Director
- Tenure: 2.1yrs
- Compensation: €57.00k
Company Information
Chr. Hansen Holding A/S's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Chr. Hansen Holding A/S
- Ticker: CHR
- Exchange: CPSE
- Founded: 1874
- Industry: Specialty Chemicals
- Sector: Materials
- Market Cap: ø69.188b
- Shares outstanding: 131.69m
- Website: https://www.chr-hansen.com
Number of Employees
Location
- Chr. Hansen Holding A/S
- Bøge Allé 10-12
- Hørsholm
- Capital Region of Denmark
- 2970
- Denmark
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| CHR | CPSE (OMX Nordic Exchange Copenhagen) | Yes | Share Capital | DK | DKK | Jun 2010 |
| 51C | DB (Deutsche Boerse AG) | Yes | Share Capital | DE | EUR | Jun 2010 |
| 0MR6 | LSE (London Stock Exchange) | Yes | Share Capital | GB | DKK | Jun 2010 |
| CRTS.F | OTCPK (Pink Sheets LLC) | Yes | Share Capital | US | USD | Jun 2010 |
| CHRC | BATS-CHIXE (BATS 'Chi-X Europe') | Yes | Share Capital | GB | DKK | Jun 2010 |
| CHYH.Y | OTCPK (Pink Sheets LLC) | SPONSORED ADS | US | USD | May 2012 |
Biography
Chr. Hansen Holding A/S, a bioscience company, develops and sells natural ingredient solutions for food, nutritional, pharmaceutical, and agricultural industries in Europe, the Middle East, Africa, North A ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/12/10 21:57 |
| End of Day Share Price | 2019/12/10 00:00 |
| Earnings | 2019/08/31 |
| Annual Earnings | 2019/08/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.